Swiss biotech AC Immune sets IPO pricing range

Sept 13 (Reuters) - AC Immune SA on Tuesday set the pricing

range for its keenly awaited U.S. initial public offering,

valuing the Swiss biotech firm at about $700 million at the top

end of the range.

Read more